vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Life360, Inc. (LIF). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $146.0M, roughly 1.7× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs 11.1%, a 77.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 26.4%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $29.1M). Over the past eight quarters, Life360, Inc.'s revenue compounded faster (36.6% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
ANIP vs LIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $146.0M |
| Net Profit | $27.5M | $129.7M |
| Gross Margin | — | 75.1% |
| Operating Margin | 14.1% | 6.1% |
| Net Margin | 11.1% | 88.8% |
| Revenue YoY | 29.6% | 26.4% |
| Net Profit YoY | 367.5% | 1425.9% |
| EPS (diluted) | $1.14 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $146.0M | ||
| Q3 25 | $227.8M | $124.5M | ||
| Q2 25 | $211.4M | $115.4M | ||
| Q1 25 | $197.1M | $103.6M | ||
| Q4 24 | $190.6M | $115.5M | ||
| Q3 24 | $148.3M | $92.9M | ||
| Q2 24 | $138.0M | $84.9M | ||
| Q1 24 | $137.4M | $78.2M |
| Q4 25 | $27.5M | $129.7M | ||
| Q3 25 | $26.6M | $9.8M | ||
| Q2 25 | $8.5M | $7.0M | ||
| Q1 25 | $15.7M | $4.4M | ||
| Q4 24 | $-10.3M | $8.5M | ||
| Q3 24 | $-24.2M | $7.7M | ||
| Q2 24 | $-2.3M | $-11.0M | ||
| Q1 24 | $18.2M | $-9.8M |
| Q4 25 | — | 75.1% | ||
| Q3 25 | — | 78.0% | ||
| Q2 25 | — | 78.4% | ||
| Q1 25 | — | 80.6% | ||
| Q4 24 | — | 74.0% | ||
| Q3 24 | — | 75.4% | ||
| Q2 24 | — | 75.0% | ||
| Q1 24 | — | 76.7% |
| Q4 25 | 14.1% | 6.1% | ||
| Q3 25 | 15.9% | 4.6% | ||
| Q2 25 | 6.6% | 1.7% | ||
| Q1 25 | 13.3% | 2.1% | ||
| Q4 24 | -2.3% | 4.9% | ||
| Q3 24 | -13.8% | -5.3% | ||
| Q2 24 | 3.7% | -2.8% | ||
| Q1 24 | 14.8% | -8.2% |
| Q4 25 | 11.1% | 88.8% | ||
| Q3 25 | 11.7% | 7.9% | ||
| Q2 25 | 4.0% | 6.1% | ||
| Q1 25 | 8.0% | 4.2% | ||
| Q4 24 | -5.4% | 7.4% | ||
| Q3 24 | -16.3% | 8.3% | ||
| Q2 24 | -1.7% | -12.9% | ||
| Q1 24 | 13.2% | -12.5% |
| Q4 25 | $1.14 | $1.53 | ||
| Q3 25 | $1.13 | $0.11 | ||
| Q2 25 | $0.36 | $0.08 | ||
| Q1 25 | $0.69 | $0.05 | ||
| Q4 24 | $-0.45 | $0.14 | ||
| Q3 24 | $-1.27 | $0.09 | ||
| Q2 24 | $-0.14 | $-0.15 | ||
| Q1 24 | $0.82 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $494.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $548.2M |
| Total Assets | $1.4B | $959.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $494.3M | ||
| Q3 25 | $262.6M | $455.7M | ||
| Q2 25 | $217.8M | $432.7M | ||
| Q1 25 | $149.8M | $168.9M | ||
| Q4 24 | $144.9M | $159.2M | ||
| Q3 24 | $145.0M | $159.0M | ||
| Q2 24 | $240.1M | $160.8M | ||
| Q1 24 | $228.6M | $73.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $5.2M |
| Q4 25 | $540.7M | $548.2M | ||
| Q3 25 | $505.8M | $391.4M | ||
| Q2 25 | $436.8M | $366.7M | ||
| Q1 25 | $418.6M | $376.3M | ||
| Q4 24 | $403.7M | $358.5M | ||
| Q3 24 | $405.9M | $339.7M | ||
| Q2 24 | $455.8M | $326.7M | ||
| Q1 24 | $452.0M | $239.8M |
| Q4 25 | $1.4B | $959.7M | ||
| Q3 25 | $1.4B | $787.5M | ||
| Q2 25 | $1.3B | $753.6M | ||
| Q1 25 | $1.3B | $455.4M | ||
| Q4 24 | $1.3B | $441.6M | ||
| Q3 24 | $1.3B | $427.4M | ||
| Q2 24 | $920.8M | $405.9M | ||
| Q1 24 | $914.5M | $318.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $36.8M |
| Free Cash FlowOCF − Capex | $29.1M | $36.6M |
| FCF MarginFCF / Revenue | 11.8% | 25.1% |
| Capex IntensityCapex / Revenue | 0.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.28× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $86.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $36.8M | ||
| Q3 25 | $44.1M | $26.4M | ||
| Q2 25 | $75.8M | $13.3M | ||
| Q1 25 | $35.0M | $12.1M | ||
| Q4 24 | $15.9M | $12.3M | ||
| Q3 24 | $12.5M | $6.3M | ||
| Q2 24 | $17.4M | $3.3M | ||
| Q1 24 | $18.3M | $10.7M |
| Q4 25 | $29.1M | $36.6M | ||
| Q3 25 | $38.0M | $25.6M | ||
| Q2 25 | $71.8M | $12.7M | ||
| Q1 25 | $32.5M | $11.9M | ||
| Q4 24 | $13.5M | $11.2M | ||
| Q3 24 | $7.7M | $6.3M | ||
| Q2 24 | $13.0M | $3.2M | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | 25.1% | ||
| Q3 25 | 16.7% | 20.6% | ||
| Q2 25 | 34.0% | 11.0% | ||
| Q1 25 | 16.5% | 11.5% | ||
| Q4 24 | 7.1% | 9.7% | ||
| Q3 24 | 5.2% | 6.8% | ||
| Q2 24 | 9.4% | 3.8% | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | 0.2% | ||
| Q3 25 | 2.7% | 0.6% | ||
| Q2 25 | 1.9% | 0.6% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 1.0% | ||
| Q3 24 | 3.2% | 0.0% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 0.0% |
| Q4 25 | 1.10× | 0.28× | ||
| Q3 25 | 1.66× | 2.70× | ||
| Q2 25 | 8.87× | 1.90× | ||
| Q1 25 | 2.23× | 2.75× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
LIF
Segment breakdown not available.
